Pugs are highly predisposed to corneal disorders, such as brachycephalic ocular syndrome (BOS), due to their disproportionate skull, reduced corneal sensitivity and eyelid anomalies such as distichiasis, entropion and lagophthalmos. The risk of corneal disorders which cause significant suffering is substantial, prompting calls for international efforts to reduce their prevalence. While these debilitating conditions are also likely to be common in pugs in Australia, their prevalence and risk factors have not been reported. The anonymised electronic patient records (EPRs) of 1318 pugs attending 139 primary care veterinary clinics participating in VetCompass Australia (VCA) in 2017 were used to investigate the prevalence of ophthalmological pathologies and associated demographic risk factors. Pugs were diagnosed with overweight/obesity (prevalence: 20.2%, 95% confidence interval {CI}: 18.1-22.4) ophthalmological abnormalities (14.5%, 95% CI: 12.6-16.3), particularly corneal disorders (12.4%, 95% CI: 12-15.7), and other conditions. The most prevalent ophthalmological disorders were corneal ulcers (5.5%, 95% CI: 4.4-6.9), corneal pigmentation (3.6%, 95% CI: 2.8-4.8) and keratoconjunctivitis sicca (KCS) (3.3%, 95% CI: 2.5-4.5). The risk of all corneal disorders increased with age (odds ratio 1.11, 95% CI: 1.07-1.15), and corneal pigmentation, KCS and keratitis were more prevalent in older pugs (a median age of 7.6 years or older), while entropion, neovascularisation and ulcerative keratitis affected younger dogs (a median age of 3 years or under). The underlying BOS conformation defects, exophthalmos, lagophthalmos and distichiasis, and early signs of corneal damage should be identified through detailed examinations during primary care veterinary visits, and affected pugs should be removed from the breeding population and treated to reduce the severity and duration of their suffering.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11851709 | PMC |
http://dx.doi.org/10.3390/ani15040531 | DOI Listing |
Clin Exp Ophthalmol
March 2025
Department of Ophthalmology, New Zealand National Eye Centre, Faculty of Medical and Health Science, The University of Auckland, Auckland, New Zealand.
Corneal dystrophies are a group of predominantly rare inherited disorders. They are by definition bilateral, relatively symmetrical, and without systemic involvement, affecting corneal transparency and/or refraction. Traditional classification of corneal dystrophies is based on slit-lamp appearance, affected corneal layer and histological features.
View Article and Find Full Text PDFHealthcare (Basel)
March 2025
Department of Cardiology, University of Medicine and Pharmacy, 300041 Timișoara, Romania.
Background/objectives: Transepithelial accelerated corneal crosslinking (TE-ACXL) is a minimally invasive approach for stabilizing progressive keratoconus while preserving the corneal epithelium. This study aims to evaluate changes in visual acuity, refractive error, and corneal parameters before and six months after TE-ACXL.
Methods: A retrospective analysis was conducted on 30 eyes from 20 patients who underwent TE-ACXL between May 2021 and June 2023.
Diagnostics (Basel)
March 2025
Department of Ophthalmology, Blanton Eye Institute, Houston Methodist Hospital, Houston, TX 77030, USA.
Oculomics is an emerging field that leverages ophthalmic imaging data to identify biomarkers of systemic disease, facilitating early diagnosis and risk stratification. Despite its growing recognition, gaps remain in the literature regarding the clinical applications of oculomics. Various systemic diseases-including metabolic disorders (e.
View Article and Find Full Text PDFBMC Ophthalmol
March 2025
Department of Ophthalmology, Kayseri City Hospital, Kayseri, Turkey.
Purpose: To analyze the refractive outcomes and changes in corneal aberrations after PRK and SMILE surgeries, and to compare these two methods.
Patients And Methods: This retrospective comparative study investigated patients aged 20-40 years who underwent SMILE or PRK for the correction of myopia between - 1.00 D and - 2.
Biomed Pharmacother
March 2025
Group of Pathophysiology and Therapies for Vision Disorders, Príncipe Felipe Research Center (CIPF), Eduardo Primo Yúfera 3, Valencia 46012, Spain; Joint Research Unit on Rare Diseases CIPF-Health Research Institute Hospital La Fe (IIS-La Fe), Valencia 46026, Spain; Biomedical Research Networking Center in Rare Diseases (CIBER-ER), Institute of Health Carlos III, Monforte de Lemos, 3-5. Pabellón 11, Madrid 28029, Spain; Catholic University of Valencia (UCV), Faculty of Health Sciences, Quevedo, 2, Valencia 46001, Spain. Electronic address:
Retinitis pigmentosa is a genetically heterogeneous retinal degeneration process. There is hardly any treatment available. It is associated with extensive chronic inflammation and the release of proinflammatory cytokines such as TNFα.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!